ResMed Inc. 10-K Summary: Fiscal Year Ended June 30, 2004
Business Context and Reporting Period
Company: ResMed Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2004
Business Overview: ResMed is a leading developer, manufacturer, and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing (SDB), primarily obstructive sleep apnea (OSA). The company operates globally with manufacturing facilities in Australia, Germany, and the U.S., selling products in over 60 countries. Key product lines include airflow generators (CPAP, VPAP, AutoSet), mask systems, and diagnostic products.
Key Financial Metrics
| Metric (in thousands, except per share) | Fiscal 2004 | Fiscal 2003 |
|---|---|---|
| Net Revenues | $339,338 | $273,570 |
| Gross Profit | $216,736 | $173,087 |
| Gross Margin | 64% | 63% |
| Operating Income | $85,361 | $67,240 |
| Net Income | $57,284 | $45,729 |
| Diluted EPS | $1.63 | $1.33 |
| Cash from Operations | $76,541 | $59,284 |
| Working Capital | $217,238 | $191,322 |
| Long-Term Debt | $113,250 | $113,250 |
| Cash & Equivalents | $128,907 | $114,491 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 24% to $339.3 million, driven by higher unit sales of flow generators and masks, as well as favorable foreign currency exchange rates (adding approx. $18.6 million).
- Profitability: Net income rose 25% to $57.3 million. Gross margin improved slightly to 64% due to a favorable product mix, partially offset by higher manufacturing costs from a stronger Australian dollar.
- Expenses: Selling, general, and administrative (SG&A) expenses increased 23% to $104.7 million, and R&D expenses increased 28% to $26.2 million. Both increases were partly attributable to currency fluctuations and increased personnel.
- Capital Expenditures: Capital expenditures surged to $57.2 million (from $25.6 million in 2003), primarily due to the construction of a new manufacturing facility in Sydney, Australia.
- Debt: No convertible subordinated notes were repurchased in 2004. Outstanding notes remained at $113.25 million.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects continued growth driven by increasing awareness of SDB, new product introductions, and geographic expansion. The company is investing heavily in R&D (approx. 8% of revenue) to maintain innovation.
- Legal Proceedings: Significant patent litigation with Respironics Inc. and Fisher & Paykel Healthcare was settled in 2003 with all claims dismissed. No material pending litigation was reported as of June 30, 2004.
- Risks:
- Reimbursement: Reliance on third-party payers (Medicare, Medicaid, private insurers) creates risk if reimbursement rates are reduced or denied.
- Competition: Highly competitive market with major players like Respironics and DeVilbiss; risk of product obsolescence.
- Foreign Currency: Significant exposure to the Australian dollar and Euro; fluctuations can materially impact reported sales and margins.
- Regulatory: Subject to FDA and international regulations; delays in clearance can impact product launches.
- Unusual Items: The company donated $0.5 million to the ResMed Sleep Disordered Breathing Foundation. There were no significant restructuring charges or in-process R&D write-offs in 2004.
Investor Verification Checklist
- Reimbursement Trends: Verify current and proposed changes in Medicare/Medicaid reimbursement policies for CPAP and related devices in the U.S. and key international markets.
- Currency Sensitivity: Assess the impact of the Australian dollar's strength on future gross margins, given that a majority of manufacturing costs are incurred in Australia.
- Capital Project Completion: Confirm the operational status and capacity of the new Sydney manufacturing facility to ensure it meets production forecasts.
- Competitive Landscape: Monitor new product launches from competitors (Respironics, DeVilbiss) that could threaten ResMed's market share in masks and flow generators.
- Debt Maturity: Review the terms of the $113.25 million convertible notes maturing in 2006 and the company's ability to refinance or repay if necessary.